Ergoteles LLC Myovant Sciences Ltd. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $480,527 - $540,318	19,997 New	19,997 $539,000
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $367,994 - $694,837	47,300 New	47,300 $588,000
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $294,138 - $423,890	-25,847 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $238,604 - $398,008	16,674 Added 181.77%	25,847 $402,000
Q3 2021 Nov 15, 2021	BUY	$18.94 - $26.99 $173,736 - $247,579	9,173 New	9,173 $206,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.